Research programme: antiviral vaccines - Immunotope

Drug Profile

Research programme: antiviral vaccines - Immunotope

Alternative Names: Viral haemorrhagic fever vaccine - Immunotope

Latest Information Update: 23 Sep 2014

Price : $50

At a glance

  • Originator Immunotope
  • Class Dengue vaccines; Viral vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dengue; Hepatitis B; Hepatitis C; HIV infections; Influenza virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 15 Sep 2014 Preclinical trials in Dengue (Prevention) in USA (unspecified route)
  • 15 Sep 2014 Preclinical trials in Influenza virus infections (Prevention) in USA (unspecified route) before September 2014
  • 15 Sep 2014 Preclinical trials in HIV infections in USA (unspecified route) before September 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top